Neumora Therapeutics IPO Presentation Deck
Navacaprant: Demonstrated Efficacy Across Broad Range
of Treatment Outcome Measures in Moderate-to-Severe Population
Depressive Symptom Improvement
HAMD-17 Total Score
Change from Baseline
HAMD-17 Response Rate
% 250% Reduction in HAMD-17 from Baseline
Remission
HAMD-17 Score ≤7
HAMD-6 Score (Core Symptoms)
Change from Baseline in HAMD-6
CGI-I
% of Patients with Very Much / Much Improvement
CGI-S
Change from Baseline
Anhedonia Symptom Improvement
SHAPS Total Score
Change from Baseline
Anxiety Symptom Improvement
HAM-A Total Score
Change from Baseline
Functional Improvement
SDS Total Score
Change from Baseline
Note: Prespecified statistical sensitivity analysis for moderate-to-severe patients (HAMD-17 > 22)
Week 4 Difference
(p-value)
-3.0
(0.015)
21.4%
(0.010)
14.9%
(0.014)
-2.4
(<0.001)
12.4%
(0.178)
ΝΑ
-2.4
(0.071)
-2.4
(0.035)
-2.5
(0.146)
Week 8 Difference
(p-value)
-2.8
(0.037)
25.9%
(0.007)
20.3%
(0.005)
-1.9
(0.013)
19.0%
(0.056)
-0.5
(0.041)
-4.8
(<0.001)
-1.6
(0.197)
-4.0
(0.013)
Confidential
11View entire presentation